Clinical TrialJul 15, 2026, 08:36 AM
Alpha Tau Treats First Immunocompromised Patient in ADMIRE Study
AI Summary
Alpha Tau Medical Ltd. announced the successful treatment of the first immunocompromised patient in its ADMIRE study. This clinical trial evaluates intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC) in patients who are immunocompromised due to conditions like organ transplantation or hematologic malignancies. This population faces significantly higher cSCC rates and limited treatment options, as standard immunotherapies can risk organ rejection. The ADMIRE study aims to provide a meaningful alternative for these vulnerable patients.
Key Highlights
- Alpha Tau successfully treated the first immunocompromised patient in its ADMIRE study.
- The ADMIRE study evaluates intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC).
- The procedure was performed at Banner MD Anderson Cancer Center in Gilbert, Arizona.
- Immunocompromised patients face 65- to 100-fold higher cSCC incidence than the general population.
- Standard immunotherapy is often avoided in transplant patients due to the risk of organ rejection.
- The ADMIRE study is designed to enroll up to 28 patients at up to 8 sites across the United States.
- The primary endpoint of the study is objective response rate (ORR) per RECIST v1.1.
Price Impact
More from DRTS